Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ELIGARD ® safely and effectively. See full prescribing information for ELIGARD ® . ELIGARD ® (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002
Medication labelWhy this: Advisory · dailymed-prescription
ELIGARD® is indicated for the palliative treatment of advanced prostate cancer.
- generic_name
- leuprolide acetate
- brand_name
- atrigel
- product_names
- Leuprolide Acetate, atrigel
- ndc
- 62935-753, 62935-753-75, 62935-754, 62935-754-74, 62935-755, 62935-755-75, 62935-223, 62935-223-05, 62935-221, 62935-221-04, 62935-224, 62935-224-05, 62935-303, 62935-303-30, 62935-305, 62935-305-29, 62935-304, 62935-304-30, 62935-453, 62935-453-45, 62935-454, 62935-454-44, 62935-455, 62935-455-45
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en